GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Huluwa Pharmaceutical Group Co Ltd (SHSE:605199) » Definitions » Debt-to-Asset

Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Debt-to-Asset : 0.43 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hainan Huluwa Pharmaceutical Group Co Debt-to-Asset?

Hainan Huluwa Pharmaceutical Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥742 Mil. Hainan Huluwa Pharmaceutical Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥545 Mil. Hainan Huluwa Pharmaceutical Group Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ¥3,028 Mil. Hainan Huluwa Pharmaceutical Group Co's debt to asset for the quarter that ended in Mar. 2024 was 0.43.


Hainan Huluwa Pharmaceutical Group Co Debt-to-Asset Historical Data

The historical data trend for Hainan Huluwa Pharmaceutical Group Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Huluwa Pharmaceutical Group Co Debt-to-Asset Chart

Hainan Huluwa Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial 0.14 0.19 0.28 0.30 0.42

Hainan Huluwa Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.38 0.42 0.42 0.43

Competitive Comparison of Hainan Huluwa Pharmaceutical Group Co's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Huluwa Pharmaceutical Group Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Huluwa Pharmaceutical Group Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Huluwa Pharmaceutical Group Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Hainan Huluwa Pharmaceutical Group Co's Debt-to-Asset falls into.



Hainan Huluwa Pharmaceutical Group Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Hainan Huluwa Pharmaceutical Group Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(542.115 + 739.499) / 3060.549
=0.42

Hainan Huluwa Pharmaceutical Group Co's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(741.696 + 545.493) / 3028.415
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hainan Huluwa Pharmaceutical Group Co  (SHSE:605199) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Hainan Huluwa Pharmaceutical Group Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Hainan Huluwa Pharmaceutical Group Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Yaogu 4th Road, Phase II, Yaogu Industrial Park, Haikou National High-tech Zone, Hainan Province, Haikou, CHN, 570300
Hainan Huluwa Pharmaceutical Group Co Ltd is engaged in production and sales of Chinese patent medicines and chemical drugs. The company produces medicines for children's respiratory and digestive systems. Its products include star products, calabash, gourd dad, and gourd mom.

Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Headlines

No Headlines